Longitudinal sample set and method of manufacturing and use thereof

A plasma exchange biobank with longitudinal sample sets addresses the challenges of using plasmapheresis samples for analyte detection, ensuring effective genome and proteome analysis by maintaining plasma integrity and linking donor information for disease analysis.

KR1020260161632APending Publication Date: 2026-11-09ALKAHEST INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020267034122
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-20
Filing Date
2025-03-19
Publication Date
2026-11-09

AI Technical Summary

Technical Problem

The utility and reproducibility of plasma exchange samples for analyte detection, particularly in genome and proteome analysis, were unclear due to concerns about the unintended removal of target analytes during plasmapheresis, interference from anticoagulants, and the impact of larger sample volumes on analyte concentration.

Method used

A library of plasma exchange samples is established, comprising longitudinal sample sets from multiple donors over time, with maintained plasma integrity, enabling effective analyte analysis using various analytical tools, and linked with donor information for disease analysis.

Benefits of technology

The plasma exchange biobank provides a robust tool for disease analysis, allowing reliable tracking of analyte changes over time and supporting diagnosis, prognosis, and drug development with high sensitivity and specificity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCT00002_ABST
    Figure PCT00002_ABST
Patent Text Reader

Abstract

The present disclosure provides a plurality of end-sample sets, wherein the end-sample set comprises a plurality of samples obtained from the same donor over a certain period of time.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] Pursuant to 35 USC §119(e), this application claims priority to the filing date of U.S. Provisional Application No. 63 / 567,746, filed on March 20, 2024; the disclosures of said application are incorporated herein by reference.

[0002] The present disclosure generally relates to a method, system, and library for performing analyte analysis, e.g., genomic analysis or proteomic analysis. Background Technology

[0003] Plasma, the liquid component of blood, is a useful source for detecting analytes in mammals. Plasma can be used in clinical laboratories and research to identify pathophysiological conditions, monitor drug concentrations, and identify biomarkers associated with the presence and / or progression of diseases. Containing a wide range of proteins, metabolites, and nucleic acids, plasma serves as a rich source of circulating biomarkers for detecting conditions such as inflammatory conditions, autoimmune disorders, neurodegenerative disorders, fetal abnormalities, and cancer in clinical settings. In research, plasma can be used, for example, to identify diagnostic and therapeutic targets for various diseases and disorders.

[0004] Plasma offers specific advantages over the use of whole blood or serum in the detection of analytes. Plasma is versatile and suitable as a detection matrix for a wide range of tests, including DNA and RNA analysis, proteomics, metabolomics, and coagulation studies. For example, using plasma instead of whole blood minimizes cellular interference in detection methods, thereby improving the accuracy and sensitivity of analyte detection. Additionally, plasma generally exhibits greater stability than other cell-free blood products, such as serum, which makes it a preferred choice for some analyses.

[0005] Plasma can be obtained using various methods, including centrifugation and the use of microfluidic devices, which enable miniaturized and automated plasma separation, thereby improving the speed and efficiency of analysis. Certain of these devices utilize capillary-driven blood-plasma separation, particularly for point-of-care diagnostics. Plasmapheresis is another method for obtaining plasma from subjects, and while it has specific advantages, its usefulness in obtaining stable samples for long-term longitudinal analysis has remained questionable.

[0006] The present disclosure addresses the utility of plasma samples obtained by plasma exchange and provides a method, system, and library of plasma exchange samples for analyte analysis.

[0007] Summary of the Invention

[0008] This summary is provided to introduce, in a simplified form, selected concepts further described in the detailed description below. This summary is not intended to identify all core or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.

[0009] The present disclosure provides a database comprising a library of plasmapheresis samples and data obtained therefrom. An exemplary library of the present disclosure comprises a library comprising multiple longitudinal sample sets comprising multiple samples obtained from the same donor over a period of time, for example, several years. Additionally, datasets, data collections, and systems obtained using these longitudinal sample sets are provided.

[0010] Accordingly, the present disclosure provides a library of plasma exchange samples comprising a plurality of end-sample sets, wherein the end-sample set comprises a plurality of samples obtained from the same donor over a period of time, and said samples are obtained by plasma exchange.

[0011] In some embodiments, the present disclosure provides a method for identifying an analyte associated with a phenotype of interest using a computer system comprising one or more processors and system memory, the method comprising: selecting two or more end-data sets in a database derived from two or more end-sample sets, wherein the end-sample sets comprise samples from a plurality of subjects; determining one or more analyte scores from a plurality of analytes detected in the end-data sets using the one or more processors, wherein the analyte scores correlate with the phenotype of interest; and identifying one or more analytes associated with the phenotype of interest based on the analyte scores for each end-data set.

[0012] In a specific embodiment, the analysis score is generated using one or more processors.

[0013] In a specific embodiment, the step of selecting two or more end-data sets within the database derived from two or more end-sample sets is performed using the one or more processors. In a specific embodiment, the end-sample sets to be queried are limited to samples collected over a specified period, e.g., 6 months, 1 year, 5 years, 10 years, etc.

[0014] In some embodiments, data derived from samples of the aforementioned end-sample set is stored in the database along with additional information that may be associated with the sample donor. In specific embodiments, the additional information in the database regarding the samples of the aforementioned end-sample set is anonymized.

[0015] In some embodiments, the present disclosure provides a computer system comprising one or more processors, system memory; and one or more computer-readable storage media, wherein the one or more computer-readable storage media stores computer-executable instructions that, when executed using the one or more processors, enable the computer system to implement a method for identifying a gene associated with a disease-related phenotype of interest.

[0016] In some embodiments, the present disclosure provides a computer system comprising one or more processors, system memory; and one or more computer-readable storage media, wherein the one or more computer-readable storage media stores computer-executable instructions that, when executed using the one or more processors, enable the computer system to implement a method for identifying a terminal data set associated with a phenotype of interest, and the method comprises: (a) using the one or more processors to select two or more terminal data sets in a database derived from two or more terminal sample sets, wherein the terminal sample sets comprise samples from a plurality of subjects collected over a specified period; (b) using the one or more processors to determine one or more analyte scores from a plurality of analytes detected in the terminal data sets, wherein the analyte scores are correlated with the phenotype of interest; and (c) using the one or more processors to identify one or more analytes associated with the phenotype of interest based on the analyte scores for each terminal data set.

[0017] In some embodiments, the method for identifying a terminal dataset associated with a phenotype of interest in the system further utilizes additional information in the database regarding samples of the terminal sample set. In specific embodiments, the method for identifying a terminal dataset associated with a phenotype of interest in the system further includes additional information that may be associated with the sample donor. In specific embodiments, the additional information in the database regarding samples of the terminal sample set is anonymized.

[0018] Other features, details, utility, and benefits of the claimed subject matter will become apparent from the following detailed description, which includes the embodiments illustrated in the attached drawings and defined in the attached claims. Brief explanation of the drawing

[0019] Drawings are not necessarily drawn to scale, and similar reference numbers should be understood to refer to similar features. Figure 1 illustrates an exemplary workflow used in the development of a model characterizing the molecular profile of a given disease. Figure 2 illustrates a plot of available plasma exchange donations for each donor with a given disease. The dotted line indicates the date of initial diagnosis for the disease. Figure 3 is a diagram illustrating exemplary additional information that may be associated with a plasma donor sample. Figure 4 illustrates a de-identification process that allows selected donor information to be associated with each of their respective samples. Figure 5 illustrates an example of correlating health status information for a given donor with molecular information contained in their plasma exchange donor samples. FIG. 6 illustrates exemplary diseases that occurred in donors during the sample collection period. The number of samples depicted as exceeding 100,000 is not drawn to scale, and, for example, a specific disorder depicted has more than 300,000 samples within the collection. Figure 7 shows a tornado plot for chronic kidney disease in the above-mentioned plasma exchange biobank. Figure 8 shows a tornado plot for Type 1 Diabetes displayed in the above plasma exchange biobank. Figure 9 shows a tornado plot for Type 2 Diabetes displayed in the above plasma exchange biobank. FIG. 10 is a schematic representation of a computer system that can be used with the method and system described herein. Figures 11a and 11b are sets of component plots illustrating detectable age-related changes in 247 cross-sectional samples from the plasma exchange biobank. Figures 12a and 12b show exemplary examples regarding the detection of longitudinal molecular changes reflecting life events. Figure 13 is a visualization of plasma samples in the above plasma exchange biobank for 1,497 donors with Parkinson's disease ("PD"). Figure 14 shows a funnel graph with initial criteria for defining a PD cohort from the plasmapheresis biobank for further study. Figure 15 is a visualization of plasma samples from 348 donors selected from the plasma exchange biobank using the criteria of Figure 14. Figure 16 summarizes the characteristics of the PD samples and control samples used in the longitudinal study of Examples 4 and 5. Figures 17a and 17b show samples collected in relation to clinical PD progression for PD patients and their respective control samples. Figure 18 shows SomaScan of plasmapheresis samples over a multi-year period. TM This is a PLS-DA component plot for PD subjects and their matched control subjects according to the analysis. Specific details for implementing the invention

[0020] The following examples merely illustrate particularly preferred methods and selected embodiments in connection therewith. The following examples should not be construed as limiting the scope of the claims.

[0021] In the following description, numerous specific details are provided to provide a more thorough understanding of the present disclosure. However, it will be apparent to those skilled in the art that the present disclosure may be practiced without one or more of these specific details. In other cases, features and procedures well known to those skilled in the art have not been described to avoid obscuring the invention. The terms used herein are intended to have the plain and ordinary meanings as understood by those skilled in the art.

[0022] All features described in connection with one embodiment of the system and / or method described herein are intended to be applicable to additional embodiments of said system and / or method, except where explicitly mentioned or where such feature or feature is incompatible with said additional embodiments. For example, where a given feature or feature is explicitly described in connection with one embodiment but not explicitly mentioned in connection with an alternative embodiment, it should be understood that said feature or feature may be placed, used, or implemented in connection with said alternative embodiment, unless said feature or feature is incompatible with said alternative embodiment.

[0023] Note that, as used in the present invention and the appended claims, the singular form includes multiple objects unless the context clearly indicates otherwise. Accordingly, for example, a reference to "object" may refer to one or more objects (depending on the context), and a reference to "system" includes references to equivalent steps, methods, and apparatus known to a person skilled in the art, and likewise below.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as generally understood by a person skilled in the art to which this disclosure pertains. All publications mentioned herein are cited by reference for all purposes, including those describing and disclosing apparatus, formulations, and methodologies that may be used in connection with the disclosures described herein. For the procedures described herein, conventional methods provided in the art and demonstrated in examples and various general literature are used. Unless otherwise noted, nucleic acid sequences described herein are presented in the 5' to 3' direction when read from left to right. Nucleic acid sequences may be provided as DNA, as RNA, or as a combination of DNA and RNA (e.g., chimeric nucleic acid) and may contain non-natural nucleotides and / or bases. Unless otherwise noted, protein sequences described herein are presented in the N-terminus to C-terminus direction when read from left to right. Protein sequences may contain non-natural amino acids and may contain chemical modifications with varying degrees of modification at specific locations within the sequence.

[0025] The term “and / or” as used herein is to be understood as specifically disclosing each of a number of specified features or components, either together with or without others. Accordingly, the term “and / or” as used herein in phrases such as “A and / or B” is intended to include “A and B,” “A or B,” “A (alone),” and “B (alone).” Likewise, the term “and / or” as used herein in phrases such as “A, B, and / or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0026] As used herein, the term “about” applied to one or more values ​​of interest refers to a value within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less than that in either direction (greater or smaller) of the mentioned reference value, unless otherwise stated or otherwise evident from the context (except where such a figure exceeds 100% of the possible value).

[0027] A person skilled in the art will understand that, generally, the terms used herein, particularly in the appended claims (e.g., the body of the appended claims), are generally intended to be "open-ended" terms (e.g., the term "including" is to be interpreted as "including but not limited thereto," the term "having" is to be interpreted as "having at least one," and the term "includes" is to be interpreted as "including but not limited thereto," etc.). A person skilled in the art will also understand that if a specific number of claims is intended to be introduced, such intent will be explicitly stated in the claims, and if there is no such statement, such intent does not exist. For example, for the sake of understanding, the appended claims below may include the use of the introductory phrases "at least one" and "one or more" to introduce claims. However, the use of such phrases, even when the same claim includes the introductory phrases "one or more" or "at least one" and indefinite articles such as "a" or "an," must not be interpreted to mean that the introduction of a claim description by the indefinite articles "a" or "an" limits any particular claim containing such introduced claim description to an embodiment containing only one such description (e.g., "a" and / or "an" should be interpreted to mean "at least one" or "one or more"); the same applies to the use of definite articles used to introduce claim descriptions. Furthermore, even if a specific number of introduced claim descriptions is explicitly stated, a person skilled in the art will recognize that such statement should be interpreted to mean at least the number stated above (e.g., stating "two descriptions" without other modifiers means at least two descriptions, or two or more descriptions).

[0028] Furthermore, where a feature or aspect of the present disclosure is described in the form of a Markush group, a person skilled in the art will recognize that the present disclosure is thereby also described in the form of any individual member or subgroup of said Markush group.

[0029] As understood by a person skilled in the art, for any and all purposes, such as providing a written description, all scopes disclosed herein also encompass any and all possible sub-scopes and combinations of sub-scopes. Any enumerated scope may be readily recognized as sufficiently describing and making possible that the same scope be divided into at least an equivalent 1 / 2, 1 / 3, 1 / 4, 1 / 5, 1 / 10, etc. As a non-limiting example, each scope discussed herein may be readily divided into a lower 1 / 3, a middle 1 / 3, an upper 1 / 3, etc. Furthermore, as understood by a person skilled in the art, all expressions such as “less than,” “at least,” “greater than,” “less than,” etc., include the stated number and refer to a scope that may subsequently be divided into sub-scopes as discussed above. Finally, as understood by a person skilled in the art, a scope includes each individual member. Accordingly, for example, a group having 1 to 3 items refers to a group having 1, 2, or 3 items. Similarly, a group having 1 to 5 items refers to a group having 1, 2, 3, 4, or 5 items, and likewise.

[0030] Although devices and methods have been or will be described with functional descriptions for the sake of grammatical fluidity, claims should not be interpreted as necessarily being limited in any way by constructs of "means" or "steps" limitation unless explicitly written under 35 USC §112, and the full scope of the definition and equivalents provided by the claims should be given under the judicial principle of the doctrine of equivalents, and where claims are explicitly written under 35 USC §112, it should be explicitly understood that full statutory equivalents under 35 USC §112 should be given.

[0031] Summary of the Invention

[0032] Plasma exchange is an in vitro technique involving the removal and processing of plasma or its components from the circulatory system and the return or exchange of these components back into the circulatory system. During a plasma exchange session, the patient's blood is drawn from the subject and introduced into an apheresis system at a peripheral or central access site. The separation of plasma from other blood components can be performed using two distinct primary techniques: centrifugation and membrane separation (Ward, DM Conventional apheresis therapies: A review. J. Clin . Apher . 2011, 26 , 230-238).

[0033] In the centrifugation method, blood is centrifuged in a component collection device, and different components are separated by specific gravity. In the membrane separation method, blood passes through a non-selective microporous membrane, which allows the passage of molecules with a weight less than a certain amount and also allows the retention of blood cells. After the plasma is separated from the blood cells, the blood cells are mixed with a liquid to replace the plasma and returned to the object from which the blood was collected.

[0034] However, prior to the experimental data presented in this disclosure, it was unclear whether plasma exchange samples could be effective samples for various analyses, including genome analysis and proteome analysis, due to the nature of the process and the properties and limitations of the plasma samples resulting therefrom.

[0035] For example, plasmapheresis is used therapeutically to remove excess antibodies, abnormal proteins, or other harmful substances from blood, and is commonly used in this way to treat certain types of blood disorders, autoimmune disorders, neurological disorders, kidney diseases, or other conditions. Because this "therapeutic plasmapheresis" non-specifically removes plasma molecules (containing pathogenic molecules), it was unclear whether obtaining plasma samples using plasmapheresis would abnormally distort analyses using the plasmapheresis samples due to the unintended removal of target analytes.

[0036] The potential utility and reproducibility of using plasmapheresis samples for analyte detection were also unclear due to specific additives added to the plasma that are necessary for successful sample collection. During plasmapheresis, foreign surfaces on the tubing of the apheresis device can activate platelets and the coagulation cascade, leading to thrombus formation. Anticoagulants such as citrates and heparin are used to prevent coagulation in extracorporeal circulation and to maintain fluidity while the blood is being processed. Depending on the anticoagulant and device used, it was believed that the addition of these anticoagulants could interfere with the detection and / or quantification of specific analytes in plasmapheresis samples.

[0037] In addition, the volume of liquid obtained during the plasmapheresis process is significantly larger than that of venous whole blood collection, and the impact of collection and storage in such a larger volume potentially affects the concentration of analytes in the sample, so this was also a concern regarding the use of plasmapheresis samples.

[0038] The present disclosure shows that plasma exchange samples can actually be effectively used for analyte analysis, e.g., proteome analysis and genome analysis, and that such analysis can reliably track changes in analytes over time in subjects.

[0039] The present disclosure demonstrates that plasma exchange samples obtained from a donor in which plasma integrity is maintained enable the successful use of various analytical tools and are therefore essentially equivalent to plasma obtained by other methods, e.g., centrifugation following venous collection of whole blood. Specifically, the present disclosure provides a library of plasma exchange samples that can be successfully used for disease analysis and analyte detection.

[0040] Library and plasma exchange biobank samples

[0041] The library and plasma exchange biobank of the present disclosure contain multiple distinct samples from multiple individuals over a specified period. The number of distinct samples within a given sample library of the present invention may vary, but in some cases, the number of distinct samples within the library comprises 1,000,000 or more, e.g. 2,000,000; 5,000,000 or more, e.g. 10,000,000 or more; and 100,000,000 or more. Two samples are "distinct" if they differ from each other, for example, in that they were obtained from different donors or from the same donor at different times.

[0042] The aforementioned separate samples can be aggregated to form a large-scale sample library constituting a "plasma exchange biobank" of plasma samples. Thus, the "plasma exchange biobank" is a collection of plasma samples derived from at least 100,000, preferably 500,000, 1,000,000, 1,500,000, 2,000,000, 2,500,000, or more than 3 million donors, providing a unique opportunity to study the preclinical and clinical stages of diseases over many years. Currently, the applicant has created a plasma exchange biobank containing over 80 million samples dating back to 2010. This establishes the applicant's plasma exchange biobank as an extensive collection of separate samples from individuals that provides a useful tool for numerous medical uses, including diagnosis, prognosis, treatment, and drug development applications.

[0043] One advantage of plasmapheresis donation compared to whole blood or plasma donation is that the intervals between donations can be shorter. For example, while whole blood is typically donated every 56 days or about once every two months, and plasma donors are typically donated every 28 days, samples obtained through apheresis can be donated twice a week, every 7 days, or up to 24 times over a 12-month period. This provides the ability to obtain more samples from the donor over a specified period and offers a more robust longitudinal sample set from individual donors.

[0044] The above plasma exchange biobank contains stored data from multiple end-sample sets obtained from individual donors. A "end-sample set" includes multiple samples obtained from the same donor over a certain period. Generally, a given end-sample set consists of multiple distinct samples obtained from the same donor over a certain date range. The number of distinct samples constituting a given end-sample set may vary, but in some cases, the number of distinct samples constituting a given end-sample set is two or more samples, five or more samples, ten or more samples, twenty or more samples, or fifty or more samples. The period (i.e., date range) over which a given end-sample set is collected may vary. In some cases, the period includes one year or more, e.g., five years or more, ten years or more, e.g., fifteen years or more, e.g., twenty years or more.

[0045] The data set obtained from the aforementioned longitudinal sample set may include any data derived from the set using various analytical methods, e.g., various "omics" methods, which provide information regarding the presence and / or abundance of one or more analytes within the longitudinal sample set. This longitudinal data set may be used to determine one or more analyte scores (e.g., presence and / or quantitative data for said analytes from individual samples) from a plurality of analytes detected in said longitudinal data set. Such analyte scores may be generated using a computer system, for example as described in more detail herein, and may be correlated with various phenotypes based on a query of said longitudinal data set.

[0046] A distinct advantage of plasmapheresis donation is that samples can be obtained in a shorter period than is typically required between whole blood sample donations. Accordingly, in some cases, a terminal sample set includes samples obtained from the donor with a minimum collection interval between any two samples in the set. In other words, the distinct samples constituting a given terminal sample set are samples obtained from the donor with a shortened time duration, for example, a minimum interval, between the times when the samples were obtained from the donor. The minimum interval may vary, but in some embodiments, the minimum interval is 2 days or more, for example, 5 days or more. The samples constituting a given terminal sample set may be obtained from the donor according to a regular or irregular schedule.

[0047] Any two given sets of end samples are considered "separate" if they consist of samples obtained from different donors, i.e., separate entities. The number of separate end sample sets present in a given sample library of the present invention may vary, but in some cases, the number of separate end sample sets present in the sample library includes 100 or more, 500 or more, e.g., 1,000 or more, e.g., 10,000 or more, e.g., 100,000 or more, e.g., 500,000 or more, 1,000,000 or more. In such cases, the sample library consists of a longitudinal sample set obtained from donors including more than 100 different donors, for example more than 500 different donors, for example more than 1,000 different donors, for example more than 10,000 different donors, for example more than 100,000 different donors, for example more than 500,000 different donors, and more than 1,000,000 different donors.

[0048] In some embodiments, the plurality of longitudinal sample sets comprises longitudinal sample sets obtained from geographically diverse donor groups. While geographically diverse donor groups may vary, the geographically diverse donor groups that may be displayed in the sample library may be from different countries or different geographical regions of the same country.

[0049] A specific longitudinal sample set of the present disclosure is characterized in that at least the initial sample of a given set was obtained from said donor when there was no disease reported to said donor. “At least initial” means that at least the first sample (i.e., the initial sample obtained at the start of said period) was obtained prior to the clinical diagnosis of the relevant disease or disorder, and in some cases, “at least initial” refers to the first 5% or more, e.g. 10% or more, e.g. 15% or more of the samples obtained from said donor.

[0050] In some cases, all or the majority of samples in a given sample set are obtained from said donor when the donor has not reported a clinical diagnosis of the specific disease condition being analyzed. Thus, in a particular embodiment, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, more than 95%, or more than 100% of the samples constituting a given longitudinal sample set may be obtained from a donor without a reported disease. Where samples are obtained from a donor without a clinical diagnosis of the relevant disease, such samples are obtained from a donor who reported having any disease at the time of sample collection.

[0051] The above plasma exchange samples commonly contain added anticoagulants such as sodium citrate, EDTA, and heparin. Where present, said added anticoagulant may be present in an amount with a citrate concentration in the range of 2% to 4%, e.g., 68 mmol / L to 136 mmol / L. Sample donors may vary, and in some cases, said samples are obtained from mammalian donors, i.e., they are mammalian samples. As used herein, the terms “mammal” and “of mammals” are used broadly to describe organisms belonging to the class Mammalia, including Carnivora (e.g., dogs and cats), Rodentia (e.g., mice, guinea pigs, and rats), and Primates (e.g., humans, cynomolgus, chimpanzees, and monkeys). In a specific embodiment, said samples are human samples.

[0052] The volume of the sample contained in the sample library may vary and may differ from the total volume of plasma obtained from the subject at the time of collection. In some cases, the volume in the sample is 1 ml or more, e.g., 2 ml or more, and in some cases, the volume is in the range of 1 mL to 10 mL, e.g., 1 to 3 mL. This volume may be a portion of the total volume obtained from the subject through plasma exchange (e.g., a portion taken from a larger collected sample of about 750 ml). The sample may be in any suitable container, e.g., a vial, a bottle, etc. In a specific embodiment, the container is a tube capable of holding up to 5 mL of a liquid, such as the liquid sample.

[0053] In some embodiments, the end sample set is stable under long-term storage. Storage stability means that the sample is chemically and physically stable for a storage period, for example, at least 1 year, at least 5 years, at least 10 years, at least 15 years, or at least 20 years under standard conditions. In some cases, the sample may be frozen, for example, the sample is maintained at a temperature including -20°C or lower, e.g., at -30°C or lower, or at -80°C or lower. In another embodiment, the sample may be frozen, for example, the sample is maintained at a temperature including 0°C or lower, e.g., at -10°C or lower, or at -15°C or lower.

[0054] The aforementioned distinct samples of the library or biobank may be stored in a single location or in separate locations, for example, the samples do not need to be located in the same location to constitute a terminal sample set or library. In some embodiments, the samples of the library or biobank are distributed in two or more different locations, that is, some of the samples are present in a first location and other samples are present in one or more locations different from the first location.

[0055] Exemplary Workflow

[0056] An exemplary workflow for the use of plasmapheresis samples within the library is illustrated in FIG. 1. First, plasma is collected from a donor via plasmapheresis, and the sample tubes are preferably stored for a long period, e.g., at sub-zero temperatures (101). Subsequently, individual plasmapheresis plasma samples from the individual donors are matched with relevant information via "tokens" as described in more detail herein (102), and the samples are assigned to potential disease or health conditions in a de-identified manner. Analytes are extracted from the individual samples and analyzed using applicable techniques for the identification and / or quantification of the analytes (103). For example, genomic or proteomic data may be generated from specific samples to identify and / or quantify the analyte(s) of interest within the samples. To identify analytes of clinical significance, a comparison is made between protein patterns before and after the onset of disease, or between a healthy cohort of plasma donors and a cohort with disease (104, 105). For example, actionable biomarker data can be generated to predict disease onset and provide targeted treatment strategies. This information is subsequently used in a clinical setting, for example, for disease diagnosis and / or therapeutic intervention (106).

[0057] The library of the present disclosure includes available plasmapheresis donations for individual donors over a period encompassing the identification, onset, and / or progression of a specific disease of interest. FIG. 2 illustrates a "tornado plot," where the x-axis represents the time difference in years from before the clinical diagnosis of the disease to the initial clinical diagnosis and progression. The y-axis represents each donor for whom the disease of interest has developed, arranged by row, and is aligned by the time difference from the last donor in the system to the initial diagnosis code associated with the specific disease.

[0058] Linking information on individual samples

[0059] In a specific embodiment, at least some, if not all, of the aforementioned end-sample sets in a given library are linked to actual use data of the individual from which the samples were obtained. Accordingly, for each end-sample set in the library, the end-sample set is linked, i.e., associated, with data regarding the donor from whom the end-sample set was obtained.

[0060] Information of interest that may be associated with a separate sample includes, but is not limited to: clinical trial data; real-world data (i.e., data related to the donor's health status and / or provision of medical services routinely collected from various sources such as electronic health records, billing and billing activity, product and disease registries, social determinants of health, imaging data, medical record data, and data collected from other sources such as mobile devices, wearables (e.g., pedometers, heart rate monitors, smartwatches, etc.); lifestyle data; consumer behavior data; internet usage data; geospatial data; mortality data; demographic data; and combinations thereof. In some cases, the donor data associated with a given longitudinal sample set is anonymized so that the identity of the donor is not associated with the longitudinal data set. Anonymization may be achieved using any convenient protocol. FIG. 3 illustrates an example of additional information that may be associated with a plasma donor sample. Each plasma donation originating from a donor may be linked to other sources of information that were not collected at the time and place of donation through that donor.

[0061] In a specific embodiment, the donor data is tokenized. When applied to data security, the "tokenization" process is a process of replacing sensitive data elements, such as donor identity or other protected health information, with non-sensitive equivalents—namely, tokens—that do not possess intrinsic or exploitable meaning or value. The token is a reference that is mapped back to the sensitive data through a tokenization system. Figure 4 illustrates a de-identification process leading to tokens that allow donor information to be associated with their samples without the need to know personally identifiable information (PII). The process represents two main components: a rule engine that removes or modifies data; and a mathematical function that converts the PII into a code that can be used as a token for data association in a unidirectional manner (i.e., so that it cannot be reverse-engineered).

[0062] Figure 5 illustrates a process of correlating health status information regarding a given donor with molecular information contained in their plasma donation samples. This specific example represents a donor who began donating plasmapheresis samples in a "healthy" state but eventually developed Parkinson's disease (PD) during the donation period. The clinical management of the said donor progresses toward a final PD diagnosis (indicated by observations on the "Diagnoses" track, along with events on the "Procedures" and "Medication" tracks), where changes in protein levels (indicated by additional points within the "Protein X level" track) may be associated with the progression of PD. Correlation of this information provides an opportunity to determine factors associated with the earliest signs of the disease.

[0063] Figure 6 illustrates the selection of diseases that eventually developed in the donors of the aforementioned longitudinal sample set during their sample collection period. The y-axis represents the number of donors diagnosed with a given disease, and the x-axis represents the broad indication classifications in which the disease of interest can be classified. Much more diseases are present in the sample collection, with over 25,000 ICD-10 codes (International Classification of Diseases, or "ICD") having more than 50 donors associated with each code. Figures 7 through 9 illustrate tornado plots for several different diseases indicated in the sample collection (chronic kidney disease, Type 1 diabetes, and Type 2 diabetes, respectively). These plots represent the identification and progression of specific diseases across the periods in which individual samples were collected, with varying levels of coverage.

[0064] Multi- Omics analyze

[0065] Samples present in the above library and plasma exchange biobank may undergo various analyses to determine the presence and / or abundance of analytes within separate samples of the above end-sample set. Exemplary analyte detection techniques vary depending on the nature of the analyte to be detected and may include various "omic" tests tailored to the identification of one or more analyte classes, e.g., DNA, RNA, proteins, etc.

[0066] The choice of which "omics" test to use will depend on the nature of the analyte being sought as well as the clinical or research objectives of the system being developed. In various instances, biological tests are performed on different parts of a sample to provide analyte data sets corresponding to biological tests for various analytes. Various tests are known to the average technician and are useful for querying samples.

[0067] As used herein, the term "assay" includes known biological assays and may also include computational biology approaches for converting biological information into useful inputs for systems analysis and modeling. Various preprocessing computational tools may be included in the assays described herein, and the term "assay" is not intended to be limited solely to the physical aspects of molecular technology.

[0068] Examples of such assays include, but are not limited to: whole-genome sequencing (WGS), whole-genome bisulfite sequencing (WGSB), small-RNA sequencing, quantitative immunoassay, enzyme-linked immunosorbent assay (ELISA), proximity extension assay (PEA), protein microarray, mass spectrometry, low-coverage whole-genome sequencing (lcWGS); selective tagging 5mC sequencing (WO2019 / 051484), CNV calling; tumor fraction (TF) estimation; whole-genome bisulfite sequencing; LINE-1 CpG methylation; 56 gene CpG methylation; cf-protein immuno-quantitative ELISA, SIMOA; and cf-miRNA sequencing, and a cell type or cell phenotype mixing ratio derived from any of the assays. This ability to simultaneously analyze multiple analytes (e.g., DNA, RNA, proteins, autoantibodies, metabolites, or combinations thereof) from the same sample or fraction thereof can increase the sensitivity and specificity of such body fluid tests by utilizing independent information between the signals.

[0069] In one example, cell-free DNA (cfDNA) content is evaluated by lcWGS or targeted sequencing, or by whole-genome bisulfite sequencing (WGBS) or whole-genome enzymatic methyl sequencing, cell-free microRNA (cf-miRNA) is evaluated by small RNA sequencing or PCR (digital droplet or quantitative), and levels of circulating proteins are measured by quantitative immunoassay. In one example, cell-free DNA (cfDNA) content is evaluated by whole-genome bisulfite sequencing (WGBS), proteins are measured by quantitative immunoassay (including ELISA or proximity extension assay), and autoantibodies are measured by protein microarray.

[0070] Extracellular nucleic acid molecules include cellular DNA (cfDNA) and cellular RNA (cfRNA). These molecules are typically fragmented but resist complete degradation in plasma due to protection from extracellular vesicles or binding proteins (e.g., nucleosomes for cfDNA, ribonucleoproteins for cfRNA).

[0071] Numerous cfDNA features (e.g., methylation patterns, mutations, copy number, fragment patterns, and nucleosome footprints) have been used for the non-invasive evaluation of disease diagnosis and prognosis. For example, van der Pol Y. and Mouliere F. Cancer Cell. 2019; 36:350-368; Jamshidi A. et al., Cancer Cell 2022; 40:1537-1549.e12; Shen SY et al. Nature.See 2018; 563:579-583. Biological information may also include information regarding transcription initiation sites, transcription factor binding sites, nucleosome locations or occupancy, transposase-accessible chromatin (ATAC-seq) data obtained by sequencing, histone marker data, DNase hypersensitivity sites (DHS), etc. Plasma concentrations of cfDNA may be tested as an analyte indicating the presence of pathology in various cases.

[0072] Many cfRNA features can also serve as analytes; such features are microRNA (Zhou J. et al., J. Clin . Oncol . 2011; 29:4781-4788) and circular RNA (Wang S. et al., Mol. Cancer. Zhu Y. et al., 2021; 20:13) also includes the presence, fragment copies, and alternating splicing patterns of mRNA and long non-coding RNA. Theranostics . 2021; 11:181-193; Larson MH et al., Nat. Commun . 2021; 12:2357.

[0073] In various examples, assays profiling the characteristics of cfDNA and / or cfRNA are used to generate signatures useful for computational applications. In one example, the characteristics of cf-DNA are used in machine learning models and to generate classifiers to stratify individuals or detect diseases, as described herein. Exemplary signatures include, but are not limited to, those providing biological information regarding gene expression, 3D chromatin, chromatin status, copy number variations, tissue of origin, and cell composition in cfDNA samples. Indicators of cfDNA concentration that can be used as input signatures for machine learning methods and models include methods for quantifying dsDNA within a specific size range (e.g., Agilent TapeStation TM , Bioanalyzer, Fragment Analyzer), a method for quantifying all dsDNA using dsDNA-binding dyes (e.g., QuantiFluor TM It can be obtained by a method including, but not limited to, PicoGreen, SYBR Green), and a method for quantifying DNA fragments (dsDNA or ssDNA) of a specific size or smaller (e.g., short fragment qPCR, long fragment qPCR, and long / short qPCR ratio).

[0074] In some embodiments, changes in gene expression are identified by measuring plasma cfDNA or cfRNA concentration levels, and methods such as microarray analysis are used to evaluate changes in gene expression levels within a sample. Indicators of cfDNA or cfRNA concentration that can be used as input signatures for machine learning methods and models include, but are not limited to, tape station, short qPCR, long qPCR, and long / short qPCR ratio.

[0075] In some embodiments, lcWGS may be used to sequence cf-DNA in a sample and then query for somatic mutations associated with specific neuropathological conditions. Somatic mutations from lcWGS, deep WGS, or targeted sequencing (by NGS or other techniques) may be used to generate data that can be used as input for an analyte signature or analyzed together with an analyte signature to identify the onset, diagnosis, prognosis, progression, etc. of a neuropathological condition in a subject.

[0076] Somatic mutation analysis enables the multiple detection of specific locus information in a single test. Such panel-based analysis can involve anywhere from a few to hundreds of genes in a single test. Other types of gene panels may include whole-exon or whole-gene sequencing, or genome analysis may be performed on selected classes of genes (e.g., kinome or transcription factor profiling), providing the advantage of being able to identify novel mutations in a known set of genes.

[0077] In other examples, assays are used to infer the three-dimensional structure of a genome using cell-free DNA (cfDNA). In particular, the present disclosure provides a method and system for detecting chromatin abnormalities associated with a disease or pathological condition. For example, the presence of a cfDNA fragment in a sample is considered to predict the chromatin status of the gene from which the cfDNA fragment originated, and this status may change in certain pathological disorders. Therefore, identifying changes in the chromatin status of a gene can serve as a method for identifying the presence or progression of a specific disease in a subject. The chromatin status of a gene can be predicted from the presence and location of cfDNA fragments in a sample using computer-assisted techniques. The chromatin status may also be useful for inferring gene expression in a sample. Pliner HA et al., Molecular Cell.71 (5) (2018) 858-871. Gene expression can be regulated by controlling the access of cellular machinery to transcription initiation sites. Access to transcription initiation sites can be determined by the state of the chromatin where the transcription initiation site is located. Chromatin state can be controlled through chromatin remodeling, which can condense (close) or loosen (open) the transcription initiation site. A closed transcription initiation site results in a decrease in gene expression, whereas an open transcription initiation site results in an increase in gene expression. Additionally, the length of cfDNA fragments can vary depending on the chromatin state. Chromatin remodeling can occur through modifications of histones and other related proteins. Non-limiting examples of histone modifications that can control the state of chromatin and transcription initiation sites include, for example, methylation, acetylation, phosphorylation, and ubiquitination.

[0078] Gene expression is also controlled by more distal elements, such as enhancers, that interact with the transcription machinery in the 3D space of the physical genome. ATAC-seq and DNAse-seq provide measurements of open chromatin, which correlate with the binding of these more distal elements that may not be explicitly associated with specific genes. For example, ATAC-seq data can be obtained for multiple cell types and conditions and can be used to identify regions of the genome with open chromatin for various basal regions, such as active transcription initiation sites or bound enhancers or repressors.

[0079] The half-life of cfDNA released from cells may depend on the chromatin remodeling state. Therefore, the abundance of cfDNA fragments within a sample may indicate the chromatin state of the gene from which the cfDNA fragments originated (referred to herein as the "location" of the cfDNA). The chromatin state of a gene may change in a disease. Identifying changes in the chromatin state of a gene can serve as a method for identifying the presence of a disease in a subject. When comparing expressed genes with unexpressed genes, quantitative changes exist in both the number and location distribution of cell-free DNA (cfDNA) fragments.

[0080] The location of a cfDNA sequence read within the genome can be determined by "mapping" the sequence to a reference genome. Mapping can be performed with the help of computer algorithms including, for example, the Needleman-Wunsch algorithm, the BLAST algorithm, the Smith-Waterman algorithm, Burrows-Wheeler alignment, a suffix tree, or a custom-developed algorithm.

[0081] DNA methylation refers to the addition of methyl groups to DNA and is one of the most widely characterized epigenetic modifications with significant functional consequences. Typically, DNA methylation occurs at cytosine bases in nucleic acid sequences. Enzymatic methyl sequencing is particularly useful because it uses a three-step conversion that requires a smaller sample volume for analysis. Various methods for determining changes in the methylation status of nucleic acids can also be used to identify analytes within samples from the aforementioned plasmapheresis biobanks. Enzymatic methyl sequencing ("EMseq") makes it possible to characterize DNA methylation of almost every nucleotide within a genome. In certain methods, the cfDNA is subjected to conditions sufficient to convert cytosine nucleotides to uracil nucleotides by performing a bisulfite conversion, for example, by oxidizing the cfDNA. In some embodiments, the bisulfite conversion involves reduced representative bisulfite sequencing.

[0082] In another embodiment, the assay used for methylation analysis is selected from mass spectrometry, methylation-specific PCR (MSP), reduced representation bisulfite sequencing (RRBS), HELP assay, GLAD-PCR assay, ChIP-on-chip assay, restriction landmark genomic scanning, methylated DNA immunoprecipitation (MeDIP), pyrosequencing of bisulfite-treated DNA, molecular break light assay, methyl-sensitive Southern Blotting, high-resolution melting assay (HRM or HRMA), ancient DNA methylation reconstruction, whole-genome bisulfite sequencing (WGBS), or methylation-sensitive single nucleotide primer extension assay (msSNuPE).

[0083] In some embodiments, the analytes are identified using cfRNA analysis. Methods for performing this include, but are not limited to, RNA sequencing, whole transcriptome shotgun sequencing, northern blot, in situ hybridization, hybridization array, serial analysis of gene expression (SAGE), reverse transcription PCR, real-time PCR, real-time reverse transcription PCR, quantitative PCR, digital droplet PCR, microarray, NanoString mRNA analysis, FISH assay, or combinations thereof.

[0084] "Quantitative" amplification methods are various suitable methods. For example, quantitative PCR involves simultaneously co-amplifying a known amount of a control sequence using the same primers. This provides an internal standard that can be used to calibrate the PCR reaction. A detailed protocol for quantitative PCR is Innis et al. (1990). PCR Protocols, A Guide to Methods and Applications It is provided in (Academic Press, Inc., NY). Measurement of DNA copy numbers at microsatellite loci using quantitative PCR analysis is Ginzinger DG et al. (2000) Cancer Research. It is described in 60:5405-5409. The known nucleic acid sequence of the gene is sufficient to allow a person skilled in the art to conventionally select primers for amplifying any portion of said gene. Fluorogenic quantitative PCR may also be used in the method of the present disclosure. In fluorogenic quantitative PCR, quantification is based on the amount of fluorescent signal, e.g., TaqMan and SYBR green. Another suitable amplification method is the ligase chain reaction (LCR) (Wu and Wallace (1989) Genomics . 4: 560, Landegren et al. (1988) Science. 241:1077, and Barringer et al. (1990) Gene 89: See 117), transcription amplification (Kwoh et al. (1989) Proc . Natl . Acad. Sci USA 86: 1173), self-persistent sequence replication (Guatelli et al. (1990) Proc Nat. Acad. Sci USA 87: 1874), dot PCR, and linker adapter PCR, etc., are included but not limited thereto.

[0085] In various examples, proteins are detected using immunoassays or mass spectrometry. For example, proteins can be measured by liquid chromatography-tandem mass spectrometry (LC-MS / MS).

[0086] In various examples, proteins are protein arrays, SIMOA (Quanterix, Billerica, MA, USA), ELISA (Abcam, Cambridge, UK), Olink TM It is measured by affinity reagents or immunoassays such as (Explore HT, Uppsala, Sweden) or SomaScan (Somalogic, Boulder, CO, USA), Luminex, and Meso Scale Discovery.

[0087] In other examples, proteins in a sample are evaluated based on characteristics such as post-translational modifications, phosphorylation status, or other protein modifications that may affect their activity, localization, lifespan, etc.

[0088] In some embodiments, the protein data is normalized by a standard curve. In various examples, each protein is treated as an inherently unique immunoassay, and each has a standard curve that can be calculated in various ways. The concentration relationship is typically non-linear. The sample can then be run and calculated based on the expected fluorescence concentration in the primary sample.

[0089] Following data collection and analysis, one or more end-sample sets of the plasma exchange biobank may be associated with analytical data (e.g., "omics" data) for the samples of said end-sample sets. Thus, an end-sample set of said library may be associated with omics data for one or more samples of said end-sample sets. In such cases, one or more samples of said set may be associated with omics data for said samples, where the number of samples of a given set associated with their omics data may vary. In some cases, more than 1%, e.g., more than 5%, more than 10%, e.g., more than 25% may be associated with their respective omics data. In some embodiments, the majority of samples in a given set may be linked to their omics data, for example, more than 50%, e.g., more than 60%, e.g., more than 70%, e.g., more than 80%, e.g. more than 90%, and in some cases, all samples in a given set may be linked to their respective omics data. The omics data to which a given sample may be linked includes, but is not limited to, proteomics data (including subsets thereof, e.g., glycoproteomics, post-translational modification, oxidation state, acetylation state, methylation state, ubiquitylation state, etc.), genomics data, epigenomics data, metabolomics data, transcriptomics data, and lipidomics data.In some cases, the omics data to which the given sample is linked comprises one or more of proteomics data, genomics data, epigenomics data, metabolomics data, transcriptomics data, and lipidomics data, e.g., two or more of proteomics data, genomics data, epigenomics data, metabolomics data, transcriptomics data, and lipidomics data, e.g., three or more of proteomics data, genomics data, epigenomics data, metabolomics data, transcriptomics data, and lipidomics data, e.g., four or more of proteomics data, genomics data, epigenomics data, metabolomics data, transcriptomics data, and lipidomics data, e.g., five or more of proteomics data, genomics data, epigenomics data, metabolomics data, transcriptomics data, and lipidomics data, and in some cases, the omics data comprises proteomics data, genomics data, epigenomics data, metabolomics data, metabolomics data, Includes transcriptomics data and lipidomics data.

[0090] If necessary, the longitudinal sample set of a given library may be classified (i.e., grouped or separated) into one or more cohorts. The cohorts of interest may vary and, in some cases, include disease cohorts, age cohorts, race cohorts, sex cohorts, lifestyle cohorts, genotype cohorts, molecular cohorts, control cohorts, etc. In some embodiments, the longitudinal sample set of a given library is classified into one or more disease cohorts. The disease cohorts of interest include, but are not limited to, the following: oncological diseases, central nervous system diseases, immunological and inflammatory diseases, cardiovascular diseases, infectious diseases, respiratory diseases, and metabolic diseases.

[0091] prediction Modeling

[0092] In some embodiments, the disease prognosis, status, subtype, progression, etc. in a subject is determined by measuring the levels of two or more analytes over time in a sample of a given disease subject and applying an interpretation function to convert said biomarker levels into predicted values, which provides quantitative measurements such as the presence, progression, and severity of the disease in said subject. In specific embodiments, these qualitative measurements correlate with traditional clinical assessments for clinical diagnosis, monitoring, and / or intervention.

[0093] In some embodiments, the interpretation function is based on a predictive model. Established statistical algorithms and methods well known in the art that are useful as a model or useful for designing a predictive model include, but are not limited to: Analysis of Variance (ANOVA); Bayesian networks; boosting and Ada-boosting; bootstrap aggregation algorithms; decision tree classification techniques such as Classification and Regression Trees (CART), boosted CART, Random Forest (RF), and Recursive Partitioning Trees (RPART); Curds and Whey (CW); Curds and Whey-Lasso; and dimension reduction methods such as principal component analysis (PCA) and factor rotation or factor analysis. Discriminant analyses including Linear Discriminant Analysis (LDA), Eigengene Linear Discriminant Analysis (ELDA), and quadratic discriminant analysis; Discriminant Function Analysis (DFA); factor rotation or factor analysis; genetic algorithms; Hidden Markov Models; kernel-based machine algorithms such as kernel density estimation, kernel partial least squares algorithm, kernel matching pursue algorithm, kernel Fisher discriminant analysis algorithm, and kernel principal component analysis algorithm; linear regression and generalized linear models including or utilizing Forward Linear Stepwise Regression, Lasso (or LASSO) reduction and selection methods, and Elastic Net regularization and selection methods;glmnet (Lasso and Elastic Net regularized generalized linear models); logistic regression (LogReg); meta-learner algorithms; nearest neighbor methods for classification or regression, e.g., Kth-nearest neighbor (KNN); non-linear regression or classification algorithms; neural networks; partial least squares; rule-based classifiers; shrunken centroids (SC); slice inverse regression; Product Model Data Exchange Standard, Application Interpretation Construction (StepAIC); super principal component (SPC) regression; and Support Vector Machines (SVM) and Recursive Support Vector Machines (RSVM), etc. Additionally, clustering algorithms are well known in the field and can be used to determine object subgroups.

[0094] In some embodiments, the interpretation function is based on data-driven disease progression modeling combined with a multi-model integration method. Such modeling strategies can help reconstruct disease progression timelines and identify pathophysiological cascades of biomarkers from multi-source omics data from one or more cross-sectional and longitudinal studies, including large cohorts of patients, healthy controls, and individuals in the prodromal / risk phase. Data-driven disease progression models may be derived from one or more of the following methods: event-based models and discriminative event-based models from mixed modeling, subtype and stage inference combining clustering and disease progression models, latent time-coupled mixed models, and differential equation models. Multi-model data integration methods combine heterogeneous information from physiological, clinical, and biological datasets through multivariate statistical analysis and latent variable modeling, including partial least squares (PLS), canonical correlation analysis (CCA), and its extension Deep CCA.

[0095] Logistic regression is a well-known and commonly preferred traditional predictive modeling method for dichotomous response variables, such as comparisons between two treatments (e.g., Treatment 1 vs. Treatment 2). It can be used to model both linear and non-linear aspects of data variables and provides easily interpretable odds ratios.

[0096] Discriminant Function Analysis (DFA) uses a series of analytes as variables (roots) to distinguish between two or more naturally occurring groups. DFA can be used in an embodiment of the present invention to test analytes that differ significantly between groups. A forward step-wise DFA can be used to select a series of analytes that best distinguish between the groups being studied. Specifically, at each step, all variables can be examined to determine which variables will best distinguish between the groups. This information is then incorporated into a discriminant function represented as a root, which is an equation consisting of linear combinations of analyte concentrations for predicting group membership. The discriminant potential of the final equation can be observed as a line plot of the root values ​​obtained for each group. This approach identifies groups of analytes where changes in concentration levels define a profile, diagnose disease, and evaluate therapeutic efficacy. The DFA model can also generate a random score that classifies a new subject as "healthy" or "diseased." To facilitate the use of this score in the medical field, the score may be readjusted so that a value of 0 represents a healthy individual and a score greater than 0 represents increasing disease activity.

[0097] Classification and regression trees (CART) can be used in an embodiment of the present invention that performs a logical split (if / then) of data to generate a decision tree. All observations belonging to a given node are classified according to the most common outcome at that node. The CART results are easily interpretable because a series of if / then tree branches can be followed until classification is achieved.

[0098] Support vector machines (SVMs) may be used in an embodiment of the present invention for classifying objects into two or more classes. Examples of such classes include sets of treatment alternatives, sets of diagnostic alternatives, or sets of prognostic alternatives. Each object is assigned to a class based on its similarity (or distance from) to objects within a known training dataset, where the correct class assignment of each object is known. The measure of similarity of a new object to a known object is determined using support vectors, which potentially define a region in a high-dimensional space.

[0099] The bootstrap aggregating process is computationally simple and can be used in an embodiment of the present invention. In the first step, a given dataset is randomly resampled a specified number of times (e.g., hundreds, thousands, or more) to provide a new dataset of that number, which is referred to as a "bootstrap resampling" of the data. Each of these bootstrap resamplings of data can then be used to build a model. Then, in the example of a classification model, the class of every new observation is predicted by the number of classification models generated in the first step. The final class determination is based on a "majority vote" of the classification models; that is, the final classification decision is determined by counting the number of times a new observation is classified into a given group and taking the majority classification (at least 33% in the case of a 3-class system). In the example of logistic regression models, if logistic regression is bagged 1,000 times, there will be 1,000 logistic models, each of which will provide the probability that a sample belongs to class 1 or 2.

[0100] Curds and Whey (CW) using ordinary least squares (OLS) is another predictive modeling method that can be used in an aspect of the present invention. See L. Breiman and JH Friedman, J. Royal. Stat. Soc. B 1997, 59(1):3-54, which is incorporated herein by reference in its entirety. This method utilizes the correlation between response variables to improve predictive accuracy compared to the conventional procedure of performing individual regression of each response variable against a common set of predictor variables X. In CW, Y = XB * S, where Y = (v¾), k represents the k*th patient and j represents the j*th response (j = 1 for TJC, j = 2 for SJC, etc.), B is obtained using OLS, and S is a reduction matrix calculated from a canonical coordinate system. Another method that can be used in an embodiment of the present invention is a combination of Curds and Whey and Lasso (CW-Lasso). Instead of using OLS to obtain B as in CW, Lasso is used here, and the parameters are adjusted to the Lasso approach.

[0101] The implemented techniques described above may be useful in combination with biomarker selection techniques (e.g., forward selection, backward selection, or stepwise selection); complete enumeration of all potential panels of a given size; genetic algorithms; neural networks; gradient boosting; and large-scale language models, or they may include biomarker selection methodologies within their own techniques. These techniques may be combined with information criteria such as Akaike's Information Criterion (AIC), Bayes' Information Criterion (BIC), or cross-validation to quantify the trade-off between the inclusion of additional biomarkers and model improvement and to minimize overfitting. The generated predictive models may be validated in other studies or cross-validated in the original training study using techniques such as Leave-One-Out (LOO) and 10-Fold cross-validation (10-Fold CV).

[0102] In some aspects of the present disclosure, candidate drug targets may be identified through the use of one or more of Mendelian randomization, network-based approaches, graph-based approaches, and propagation. However, the identification of candidate drug targets is not limited to the methods described above, and the methods are listed as examples rather than limitations.

[0103] Mendelian randomization is a method that uses genetic variants as instrumental variables to evaluate the causal relationship between modifiable exposures and disease outcomes. This helps determine potential therapeutic targets. Network-based approaches have different applications, including the analysis of protein-protein interaction (PPI) networks to identify key proteins or hubs involved in disease pathways. Modeling of gene regulatory networks (GRNs) is a network-based approach to elucidate transcription factors or genes that play regulatory roles in disease processes. The investigation of metabolic networks is a network-based approach to identify metabolites or enzymes involved in disease metabolism. Furthermore, the construction of drug-target interaction networks is another network-based approach that can be used to identify potential drug targets based on drug-protein interactions.

[0104] Graph-based approaches involve analyzing interconnected relationships between entities represented as nodes and edges in a network and help identify key targets within biological systems for therapeutic intervention. Propagation diffusion involves algorithms that spread information or influence through a network and helps identify relevant nodes or entities in complex systems, such as biological networks, for potential therapeutic targeting.

[0105] In some aspects of the present disclosure, it is not required that the disease score be compared to any predetermined "reference," "normal," "control," "standard," "healthy," "pre-disease," or other similar indicator in order to provide a quantitative measure of the disease activity of the subject.

[0106] In another aspect of the present disclosure, the amount of biomarker(s) may be measured in a sample and used to derive a disease score, which is then compared to a “normal” or “control” level or value using techniques such as reference or discrimination limits or risk definition thresholds to define a cutoff point and / or abnormal value for the disease. The normal level is a level of one or more biomarkers or combined biomarker indices typically found in subjects not suffering from the disease being evaluated. Other terms for “normal” or “control” include, for example, “reference,” “indicator,” “baseline,” “standard,” “healthy,” “pre-disease,” etc. Such normal levels may vary depending on whether the biomarker is used alone or in a formula combined with other biomarkers to output a score. Alternatively, the normal level may be a database of biomarker patterns from previously tested subjects who have not developed the disease being evaluated over a preclinical or clinically relevant period. Reference (normal, control) values ​​may also be derived from control subjects or populations with known levels or conditions of disease activity. In some embodiments of the present disclosure, the reference values ​​may be derived from one or more subjects who were exposed to treatment for the disease, or from one or more subjects with a low risk of developing the disease, or from subjects who showed improvement in disease activity factors (e.g., clinical parameters defined herein) as a result of exposure to treatment. In some embodiments, the reference values ​​may be derived from one or more subjects who were not exposed to treatment. One example includes samples that may be collected from (a) subjects who received initial treatment for the disease and (b) subjects who received subsequent treatment for the disease to monitor the progress of treatment. Reference values ​​may also be derived from disease activity algorithms or calculated indices from population studies.

[0107] database

[0108] An aspect of the present disclosure further comprises a database of data and associated information (e.g., a storage in the form of a non-transient computer-readable storage medium) containing data derived from one or more end sample sets. Accordingly, an aspect of the present invention comprises a database of end data sets from one or more end sample sets, wherein the end sample set comprises a plurality of samples obtained from the same donor over a period of time, and, for example, said data includes donor data associated with said end sample set as described in more detail herein. The computer-readable storage medium may be used on one or more computers for full or partial automation of a system for carrying out the method and model as described herein.

[0109] In certain embodiments, instructions according to the method described herein may be coded in the form of “programming” on a computer-readable medium, where the term “computer-readable medium” as used herein refers to any non-transient storage medium involved in providing instructions and data to a computer for execution and processing. Examples of suitable non-transient storage media include floppy disks, hard disks, optical disks, magneto-optical disks, CD-ROMs, CD-Rs, magnetic tapes, non-volatile memory cards, ROMs, DVD-ROMs, Blu-ray disks, solid-state disks, and network-attached storage (NAS), regardless of whether such devices are inside or outside the computer. Files containing information may be “stored” on a computer-readable medium, where “stored” means recording information so that it can be accessed and retrieved by a computer later. The computer implementation method described herein may be executed using programming that may be written in one or more of any computer programming languages. Such languages ​​include, for example, Java (Sun Microsystems, Inc., Santa Clara, CA), Visual Basic (Microsoft Corp., Redmond, WA), C++ (AT&T Corp., Bedminster, NJ), Python, as well as many other languages.

[0110] The format of the above database and the manner in which data records, e.g., sample records, associated donor data, sample omics data, etc., are indicated as being related or linked to one another (since they relate to the same sample), may follow conventional database technology. The above database control unit includes a processor suitablely configured / programmed to provide the desired functions described herein using conventional programming / configuration technology for controlling database creation, maintenance, and access operations. The functions of the suitable control unit may be provided in various different ways, for example, by using a suitablely programmed general-purpose computer, a suitablely configured custom integrated circuit / circuit, or by using a plurality of individual circuits / processing elements to provide different elements of the desired functions.

[0111] A database storage unit of an embodiment of the present invention may include memory for various records constituting the database. The database storage unit may be based on any conventional memory technology, such as solid-state memory or disk-based memory such as magnetic disk or optical disk-based memory. Furthermore, the memory constituting the storage unit may, in principle, include a single memory unit, but generally, the memory constituting the storage unit may be composed of a distributed array of memory units that provide redundancy for fault recovery according to conventional technology.

[0112] computer system

[0113] As summarized above, an aspect of the present disclosure includes a system for carrying out the method, for example, for querying a database. A system according to a particular aspect includes a processor comprising a memory operably coupled to a processor, wherein the memory comprises a stored instruction, which, when executed by the processor, causes the processor to receive input from an input device and output a result to an output device, and the processor and the memory are operably connected to the input device and the output device, respectively.

[0114] The database containing the aforementioned end data set may consist of a useful data set stored on a computer-readable medium. A specific system also provides a function (e.g., code and process) for storing any result (e.g., query result) or data set generated as described herein. Such result or data set is typically stored at least temporarily on a computer-readable medium, such as that presented in the following discussion. The result or data set may also be output in various ways, such as display, printing, etc.

[0115] Examples of displays suitable for interfacing with a user according to the present invention include, but are not limited to, cathode ray tube displays, liquid crystal displays, plasma displays, touch screen displays, video projection displays, light-emitting diode and organic light-emitting diode displays, surface conduction electron emission displays, etc. Examples of printers include toner-based printers, liquid inkjet printers, solid ink printers, dye sublimation printers, as well as inkless printers such as thermal transfer printers. Printing may be performed on a medium of a type such as paper or a transparent film.

[0116] Examples of types of computer-readable media suitable for use in the computer program products and computing devices of the present invention include, but are not limited to, magnetic media such as hard disks, floppy disks, and magnetic tapes; optical media such as CD-ROM disks; magneto-optical media; semiconductor memory devices (e.g., flash memory); and hardware devices specifically configured to store and execute program instructions, such as read-only memory devices (ROM) and random access memory (RAM); and sometimes application-specific integrated circuits (ASICs), programmable logic devices (PLDs), and signal transmission media for transmitting computer-readable instructions, such as local area networks, wide area networks, and the Internet. The data and program instructions provided herein may also be implemented on carrier waves or other transmission media (including electronic or optical conduction paths). The data and program instructions of the present invention may also be implemented on carrier waves or other transmission media (e.g., optical lines, electric lines, and / or radio waves).

[0117] Examples of program instructions include low-level code, such as that generated by a compiler, as well as high-level code that can be executed by a computer using an interpreter. Additionally, said program instructions may be machine code, source code, and / or any other code that directly or indirectly controls the operation of a computing machine. said code may specify inputs, outputs, calculations, conditions, branches, loops, etc.

[0118] FIG. 10 illustrates a typical computer system in simple block form that can function as a computing device according to a particular embodiment when properly configured or designed. The computer system (1000) includes any number of processors (1002) (central processing units, also referred to as CPUs) coupled to a storage device comprising a primary storage device (1006) (typically random access memory, i.e., RAM) and a primary storage device (1004) (typically read-only memory, i.e., ROM). The CPUs (1002) may be of various types, including microcontrollers and microprocessors such as programmable devices (e.g., CPLDs and FPGAs), and non-programmable devices such as gate array ASICs or general-purpose microprocessors. In the illustrated embodiment, the primary storage device (1004) serves to transmit data and instructions to the CPU in a unidirectional manner, and the primary storage device (1006) is typically used to transmit data and instructions in a bidirectional manner. All of these primary storage devices may include any suitable computer-readable medium as described above. A mass storage device (1008) may also be coupled bidirectionally to the primary storage device (1006) to provide additional data storage capacity and may include any of the computer-readable media described above. The mass storage device (1008) may be used to store programs, data, etc., and is typically a secondary storage medium such as a hard disk. Often, such programs, data, etc., are temporarily copied to the primary memory (1006) for execution on the CPU (1002). It will be understood that information held within the mass storage device (1008) may be integrated in a standard manner as part of the primary storage device (1004) where appropriate. Certain mass storage devices, such as a CD-ROM (1014), may also unidirectionally transfer data to the CPU or the primary storage device.

[0119] The CPU (1002) is also coupled to an interface (1010), which is connected to one or more input / output devices such as a video monitor, trackball, mouse, keyboard, microphone, touch-sensitive display, transducer card reader, magnetic or paper tape reader, tablet, stylus, voice or handwriting recognition peripheral, USB port, or, of course, other well-known input devices such as another computer. Finally, the CPU (1002) may optionally be coupled to an external device such as a database or a computer or communication network using an external connection as generally indicated in 1012. Through such a connection, the CPU is considered to be able to receive information from the network or output information to the network during the process of performing the method steps described herein.

[0120] In one embodiment, a system such as a computer system (1000) is used as a data acquisition, data correlation, and query system capable of performing some or all of the tasks described herein. The system (1000) may also function as various other tools associated with knowledge bases and queries, such as data capture tools. Information and programs containing data files may be provided via a network connection (1012) for access or download by a researcher. Alternatively, such information, programs, and files may be provided to the researcher via a storage device.

[0121] In a specific embodiment, the computer system (1000) is directly coupled to a data acquisition system, such as a microarray or a high-throughput screening system, that captures data from a sample. Data from such a system is provided through an interface (1010) for analysis by the system (1000). Alternatively, data processed by the system (1000) is provided from a data storage source, such as a database or other repository of related data. Upon entry into the device (900), a memory device, such as a primary storage device (1006) or a mass storage device (1008), buffers or at least temporarily stores the related data. The memory may also store various routines and / or programs for acquiring, analyzing, and presenting data, including acquiring feature sets, correlating feature sets with each other and with feature groups, generating and executing queries, etc.

[0122] In certain embodiments, a user terminal may include any type of computer (e.g., desktop, laptop, tablet, etc.), a media computing platform (e.g., cable, satellite set-top box, digital video recorder, etc.), a portable computing device (e.g., PDA, email client, etc.), a mobile phone, or any other type of computing or communication platform. A server system communicating with a user terminal may include a server device or a distributed server device, and may include a mainframe computer, a minicomputer, a supercomputer, a personal computer, or a combination thereof. Multiple server systems may be used without departing from the scope of the present invention. The user terminal and the server system may communicate with each other through a network. Without limiting the scope of the present invention, the network may include wired networks such as LAN (local area networks), WAN (wide area networks), MAN (metropolitan area networks), ISDN (Integrated Service Digital Networks), etc., as well as wireless networks such as wireless LAN, CDMA, Bluetooth, and satellite communication networks.

[0123] In at least some of the embodiments described above, one or more elements used in one embodiment may be used interchangeably in another embodiment, unless their substitution is not technically feasible. It will be understood by those skilled in the art that various other omissions, additions, and modifications may be made to the methods and structures described above without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the said subject matter as defined by the appended claims.

[0124] Examples

[0125] The following examples are presented to provide a complete disclosure and description of the methods for manufacturing and using the present disclosure to those skilled in the art, and are not intended to limit the scope of what the inventors consider to be their invention, nor are they intended to indicate or imply that the experiments below are the only or all experiments performed. It will be understood by those skilled in the art that numerous changes and / or variations may be made to the invention as shown in specific embodiments without departing from the spirit or scope of the present disclosure as broadly described. Accordingly, the embodiments should be considered illustrative in all respects and not restrictive.

[0126] Examples 1: Creation of a Plasma Exchange Biobank

[0127] An exemplary plasma exchange biobank of the present invention was created using a large longitudinal sample set collection obtained by plasma exchange over many years. Through tokenization, the samples of this biobank were linked to various data regarding said samples and their donors in a de-identified manner in a database. This data included, but was not limited to, real-world data such as diagnostic codes (e.g., ICD-10 codes below). Examples of data used included, but were not limited to, the number of donors diagnosed by various ICD-10 codes (see Table 1) and the temporal relationship between plasma donation and disease diagnosis (e.g., see FIGS. 7 through 9). Table 1 illustrates a portion of the data derived from said biobank, including a selection of the number of diseases indicated in the sample collection as of January 2024. The aforementioned ICD-10 code refers to the International Classification of Diseases (ICD, 10th Revision), a medical classification list by the World Health Organization (WHO). It is a diagnostic tool used to classify and monitor the causes of injury and death, and to maintain information for health analyses, such as studies on mortality and morbidity trends.

[0128] ICD Codes and Number of Donors for Plasma Exchange Biobanks [ICD-10 Code] [ICD-10 Description] [Number of donors] C259 Malignant neoplasm of the pancreas, unspecified 597 C569 Malignant neoplasm of the ovary, unspecified 691 C719 Malignant neoplasm of the brain, unspecified 869 C3490 Malignant neoplasm of an unspecified portion of the bronchus 2,238 H409 Glaucoma of unspecified type 3,575 F329 Major depressive disorder, unspecified, single episode 279,138 G35 Multiple sclerosis 4,362 G20 Parkinson's disease 1,150 G300 Early-onset Alzheimer's disease 153 G309 Alzheimer's disease of unspecified type 391 I67850 Cerebral autosomal dominant arterial disease with subcortical infarction 20 F319 Bipolar disorder of unspecified type 114,631 F209 Schizophrenia of unspecified type 36,555 G1221 Amyotrophic lateral sclerosis 152 M0579 Rheumatoid arthritis with multiple rheumatoid factor 1,658 L409 Psoriasis of unspecified type 10,917 K5090 Crohn's disease, unspecified, no complications 3,668 M329 Systemic lupus erythematosus, unspecified 4,542 I10 Essential (Primary) Hypertension 374,089 I509 Heart failure of unspecified type 20,132 I739 Peripheral vascular disease of unspecified type 16,485 I4891 Atrial fibrillation of unspecified type 13,330 U071 COVID-19 217,487 J1100 Influenza caused by an unspecified influenza virus, accompanied by unspecified 810 Z227 Latent tuberculosis 848 B54 Malaria of unspecified type 53 B182 Chronic viral hepatitis C 10,181 J45909 Asthma, unspecified, no complications 175,113 J449 Chronic obstructive pulmonary disease of unspecified type 53,323 J84112 idiopathic pulmonary fibrosis 165 Z141 Cystic fibrosis carrier 1,011 E109 Type 1 diabetes without complications 5,318 E119 Type 2 diabetes without complications 105,035 K700 Alcoholic fatty liver 1,512 K7581 Non-alcoholic fatty liver disease (NASH) 3,261 K760 Fatty liver (changes) not otherwise classified 70,924

[0129] Examples 2: In Parkinson's disease biomarkers Samples from a biobank using plasma exchange for identification

[0130] Early diagnosis can be particularly useful for chronic, progressive neurodegenerative diseases where symptoms follow the early pathology of the disease. For example, approximately 60–80% of dopaminergic neurons in the subject's substantia nigra must die before noticeable Parkinson's disease symptoms appear, implying that a significant loss of these neurons is required before motor symptoms become evident. Lang AE et al. N EnglJ Med . 1998; 339:1044-1053; Dauer W et al. Neuron. See 2003; 39:889-909. Identification of such progressive neuropathological conditions through non-invasive evaluation of analytes and temporal signatures enables earlier treatment and possibly intervention before the disease state progresses to the symptomatic stage.

[0131] Parkinson's Disease Progression Marker Initiative (PPMI) Prog Neurobiol . Ongoing projects, such as 2011 Dec; 95(4):629-35), have played a significant role in identifying potential biomarkers associated with Parkinson's disease, understanding the onset of the disease, and identifying progression markers. PPMIs and study cohorts rely on detailed longitudinal follow-up of hundreds to thousands of individuals with early symptoms or an established PD diagnosis. In contrast, population-based studies, such as those associated with the UK Biobank (Sudlow C et al., PLoS Med . 2015 Mar 31; 12(3):e1001779) tracks hundreds of thousands of individuals over the entire duration of the disease, but only a tiny fraction of them will develop rare diseases such as PD. While customized research cohorts like PPMI and population-based studies using the UK Biobank are inherently complementary, they both have major limitations: the number of biological samples collected during the preclinical phase of diseases like PD is inherently extremely limited. In fact, research cohorts mostly focus on the clinical phase of the disease, whereas biological sample collection in population-based cohorts is primarily done at baseline. This hinders a longitudinal understanding of the early stages of disease progression from a molecular perspective.

[0132] These limitations were overcome in this study by using a unique set of samples that provided the ability to perform retrospective analysis on a large cohort of affected individuals spanning several years, from prior to the onset of the disease to its diagnosis and progression. The identification of analytes for use in the system and method of this disclosure was made possible by a unique asset: plasmapheresis samples collected from a cohort of over 3,000,000 individuals over 20 years, during which up to 30 samples were collected from a single individual, providing a unique opportunity for retrospective analysis of this population. Importantly, because the subjects who donated these samples were designated as phenotype-normal at the time of donation, retrospective analysis of these samples could provide molecular identification of disease onset and progression in an agnostic manner, potentially years prior to clinical identification of the disease state.

[0133] Examples 3: Confirmation of Robust Biological Signals in Samples from Plasma Exchange Biobanks

[0134] Prior to using samples from the plasma exchange biobank described in Example 1 for the identification of such predictive analytes, it was first confirmed that said samples were suitable for such analysis. Specifically, the feasibility of using said samples from the plasma exchange biobank for the analysis of neuropathological conditions was investigated by using longitudinal profiling for all stages of Parkinson's disease ("PD") and by demonstrating the experimental feasibility of measuring longitudinal molecular changes in about 700 samples from human plasma donors.

[0135] Over 58,000 samples from donors with PD were stored in the aforementioned plasmapheresis biobank, establishing the plasmapheresis biobank as the most extensive collection of biological samples from individuals with ongoing PD. Samples used for the analysis of sample integrity and subject aging processes were selected using linear regression adjusted for sex, race, storage duration, and the number of donations within 30 days. Correction for multiple comparisons was performed using the Benjamin-Hochberg (BH) adjustment, a statistical method that controls for the false discovery rate (FDR) in multiple comparisons. Benjamini, Y., & Hochberg, Y. (1995) Journal of the Royal Statistical Society: Series B (Methodological). 57(1), 289-300.

[0136] Briefly, the potential effects of age and storage conditions on the plasma proteome in stored plasmapheresis samples were measured using two proteomic detection platforms: Olink Explore HT (5k) (Olink, Uppsala, Sweden), a proteomic antibody-based detection platform capable of detecting over 5,400 proteins in plasma samples, and SomaScan, a proteomic aptamer-based detection platform capable of detecting 7,288 human proteins in plasma samples. TM assay v4.1 (Somalogic, Boulder, CO, USA). The results are shown in Figures 11a and 11b.

[0137] Age-related proteomic changes in the UK Biobank cohort (Sun, BB et al., Nature. (2023) 622, 329-338) and a meta-analysis of four independent cohorts (Coenen, L. et al., Front. Aging.It was compared to that from 4, 112109 (2023)). Proteome changes were linked to aging-associated biological events, such as menopause or cardiovascular events (shown in Figs. 12a and 12b, respectively). Plasma proteomics measurements were taken from 504 samples from 40 donors using the Somalogic SomaScan. TM Further tests were performed using a platform (Somalogic, Boulder, CO, USA). The lines in Fig. 12a and Fig. 12b connect samples from the same donor. The observed temporal molecular changes may be associated with menopause (follicle-stimulating hormone, Fig. 12a) or cardiovascular events identified by medical records (natriuretic peptide B, Fig. 12b).

[0138] These data demonstrate that samples from stored plasmapheresis biobank assets are robust and suitable for various multi-omic assays for the identification of analytes for improved drug development systems and methods. In particular, the samples were in a unique position to identify targets, pathways, and various other biological indicators that change over time in pathological conditions, and to support the development of drug development systems, tools, and reagents.

[0139] Examples 4: Longitudinal Profiling of Biological Processes for Parkinson's Disease in Samples from Plasma Exchange Biobanks

[0140] The feasibility of using samples from the above plasma exchange biobank for multi-omic analysis of neuropathological conditions was investigated by using longitudinal profiling for all stages of Parkinson's disease ("PD") and by demonstrating the experimental feasibility of measuring longitudinal molecular changes in samples from about 700 human plasma donors.

[0141] It was confirmed that over 58,000 samples from donors with PD are stored in the aforementioned plasma exchange biobank, making it one of the most extensive collections of biological samples from individuals with ongoing PD. This unique asset enabled retrospective analysis and in-depth longitudinal molecular profiling of plasma samples from these individuals with PD, providing a unique opportunity to study all stages of PD development, from onset to progression, at the molecular level. Longitudinal samples were selected from a subset of plasma donors identified as having PD and carefully matched control donors, each of which was subsequently validated across multiple proteomics technologies to discover novel preclinical analytes of PD and new candidate therapeutic targets and pathways for further drug development.

[0142] As illustrated in Fig. 13, the plasma exchange biobank was annotated with real-world data (RWD), and individual members of the sample library (each indicated by a black dot) were found to cover all stages of PD development from approximately 12 years prior to clinical diagnosis to 8 years prior to clinical diagnosis. This visualization included only donors with complete and consistent demographic information from the plasma exchange biobank. PD diagnosis was established based on the presence of at least one G20 ICD10 code in their medical records (billing or electronic health record ("EHR") data). Plasma samples were displayed based on the time of their initial PD diagnosis (G20 ICD10 code), and donors were ranked based on the time difference between their last donation and their initial PD diagnosis.

[0143] The identified data provided an initial definition of the PD cohort and were used to identify potential plasma donors likely to have developed PD (Fig. 14). The selection process included the definition of specific filtering criteria, which may include, but are not limited to, demographics, medical history (G20 codes, PD medications), and sample availability. This initial PD cohort consisted of approximately 700 donors with developed PD based on claims data. In specific cases, EHR data was used when necessary to provide additional information on donors with specific medical or proteomic patterns.

[0144] Based primarily on the above claim data, three major cohorts were defined: the established PD cohort; the expert-reviewed PD cohort; and the non-PD control group.

[0145] A data-based established PD cohort can be identified, for example, using the following set of inclusion criteria: two appearances of an ICD-10-CM code (Table 2), two or more prescriptions for PD medication (Table 3), and at least three diagnostic claims. Based on such exemplary claim data, 125 donors who made at least one plasma donation were included in the established PD cohort.

[0146] In addition, the following exemplary criteria may be used as exclusion criteria: exclusion of ICD-10-CM codes (Table 4) and exclusion of drugs that may cause symptoms similar to PD (Table 5).

[0147] The subjects considered for the aforementioned expert review cohort were selected using different approaches and machine learning algorithms based on the presence or absence of ICD10 codes related to diagnosis and medication. The health journey of each of these subjects was reviewed by CNS scientists trained to identify PD based on medical health records. 223 donors were included in the aforementioned expert review cohort.

[0148] Samples from these donors who developed PD covered all stages of PD development (Fig. 15). Plasma samples were labeled based on the time of their initial PD diagnosis (G20 ICD10 code), and donors were ranked based on the time difference between their last donation and their initial PD diagnosis.

[0149] Finally, the exclusion criteria for the above control cohort are lack of sufficient information and any ICD-10-CM codes in Tables 2 and 4 and all drugs in Tables 3 and 5.

[0150] PD of the cohort Selection and Control Group from the cohort Included ICD-10-CM codes used for donor exclusion: ICD-10-CM code explanation G20 Parkinson's disease G20.A Parkinson's disease without dyskinesia G20.A1 Parkinson's disease without dyskinesia, without mention of fluctuations G20.A2 Parkinson's disease accompanied by fluctuations and without dyskinesia G20.B Parkinson's disease accompanied by dyskinesia G20.B1 Parkinson's disease with dyskinesia without mention of fluctuations G20.B2 Parkinson's disease accompanied by fluctuations and dyskinesia G20.C Parkinson's disease of unspecified type

[0151] PD of the cohort Selection and Control Group from the cohort Parkinson's disease drugs used for donor exclusion: Exclusive drug name Non-exclusive drug name Amantadine Amantadine Gocovri Amantadine Osmolex ER Amantadine Amantadine hydrochloride (amantadine hcl) Amantadine hydrochloride Apokyn apomorphine hydrochloride Apomorphine hydrochloride Apomorphine hydrochloride Apomorphinum muriaticum Apomorphine hydrochloride Kynmobi Apomorphine hydrochloride Benztropine Benztropin benztropine mesylate Benztropine mesylate Cogentin Benztropine mesylate bromocriptine mesylate Bromocriptine mesylate Cycloset Bromocriptine mesylate Parlodel Bromocriptine mesylate Cabergoline Cabergolin Carbidopa Carbidopa Lodosyn Carbidopa Carbidopa and levodopa Carbidopa and Levodopa Duopa Carbidopa and Levodopa Pacopa Carbidopa and Levodopa Rytary Carbidopa and Levodopa Sinemet Carbidopa and Levodopa Cinemet - CR(sinemet - cr) Carbidopa and Levodopa Dhivy Carbidopa Levodopa Carbidopa, levodopa, and entacapone Carbidopa, levodopa, and entacapone Stalevo Carbidopa, levodopa, and entacapone Comtan Entacapone Entacapon Entacapon Norianz Istradefylline Inbrija Levodopa Ongentys Opicapone Pramipexole Pramipexol pramipexole dihydrochloride Pramipexol Pramipexole dihydrochloride - extended-release Pramipexol Mirapex Pramipexol dihydrochloride Mirapex ER Pramipexol dihydrochloride Pramipexol dihydrochloride Pramipexol dihydrochloride Rasagiline Rasagilin Azilect rasagiline mesylate Rasagiline mesylate Rasagiline mesylate Ropinirole Lopinirole Ropinirole hydrochloride Lopinirole Requip Ropinirole hydrochloride Requip - XL Ropinirole hydrochloride Ropinirole hydrochloride Ropinirole hydrochloride Neupro Rotigotine Xadago safinamide mesylate Emsam Selegiline Eldepryl selegiline hydrochloride Selegiline hydrochloride Selegiline hydrochloride Zelapar Selegiline hydrochloride Tasmar Tolcapone Tollcar phone Tollcar phone trihexyphenidyl hydrochloride trihexyphenidyl hydrochloride

[0152] Data-driven PD Cohort and control group In the cohort ICD-10-CM codes excluded for this (this list is also referred to as PD-like diseases): ICD-10-CM code explanation G10 Huntington's disease G12 Spinal muscular atrophy and related syndromes G12.0 Infantile spinal muscular atrophy, Type I [Werdnig-Hoffmann] G12.1 Other hereditary spinal muscular atrophy G12.2 motor neuron disease G12.20 Motor neuron disease of unspecified type G12.21 Amyotrophic lateral sclerosis G12.22 progressive medullary paralysis G12.23 Primary lateral sclerosis G12.24 Familial motor neuron disease G12.25 progressive spinal muscular atrophy G12.29 Other motor neuron diseases G12.8 Other Spinal Muscular Atrophy and Related Syndromes G12.9 Spinal muscular atrophy, unspecified G21 Secondary Parkinson's disease G21.0 malignant neuroleptic syndrome G21.1 Other drug-induced secondary parkinsonism G21.11 Neuroleptic-induced Parkinsonism G21.19 Other drug-induced secondary parkinsonism G21.2 Secondary Parkinson's disease caused by other external factors G21.3 Post-encephalitis Parkinson's disease G21.4 Vascular Parkinson's disease G21.8 Other secondary parkinsonism G21.9 Secondary Parkinson's disease, unspecified G23.1 Progressive supranuclear palsy [Still-Richardson-Olcevsky] G23.2 striatal substantia nigra degeneration G31.0 Frontotemporal dementia G31.83 Neurocognitive disorder with Lewy bodies G31.85 Corticobasal degeneration G35 Multiple sclerosis G90.3 Multisystem degeneration of the autonomic nervous system G91.2 (Idiopathic) Normal pressure hydrocephalus

[0153] Data-driven PD Cohort and control group from the cohort Parkinson's disease medications used for donor exclusion (also referred to as antipsychotics in this list): Exclusive drug name Non-exclusive drug name Abilify Abilify Abilify Aripiprazole Abilify asimtufii Aripiprazole Abilify Maintena Aripiprazole Abilify mycite Aripiprazole Aripiprazole Aripiprazole Aristada aripiprazole lauroxil aristada initio Aripiprazolauroxil Asenapine Acenafin Secuado Acenafin Acenafin Asenapine maleate Acenafin maleate Acenafin maleate Saphris Acenafin maleate Brexpiprazole Brexpiprazole Rexulti Brexpiprazole Vraylar Cariprazine Chlorpromazine Chlorpromazine chlorpromazine hydrochloride Chlorpromazine Chlorpromazinum Chlorpromazine Chlorpromazine hydrochloride (chlorpromazine hci) Chlorpromazine hydrochloride Clozapine Clozapine Clozaril Clozapine Fazaclo Clozapine Versacloz Clozapine Haldol Haloperidol Haloperidol Haloperidol Haloperidol lactate Haloperidol Haldol decanoate haloperidol decanoate haloperidol decanoate haloperidol decanoate Haldol Haloperidol lactate Haloperidol Haloperidol lactate Latuda lurasidone hydrochloride lurasidone hydrochloride lurasidone hydrochloride Olanzapine Olanzapine Zyprexa Olanzapine Zyprexa zydis Olanzapine olanzapine and fluoxetine Olanzapine and fluoxetine Symbyax olanzapine and fluoxetine hydrochloride Olanzapine and fluoxetine Olanzapine and fluoxetine Lybalvi olanzapine and samidorphan l-malate Zyprexa olanzapine pamoate Invega Paliperidone paliperidon paliperidon Invega hafyera Paliperidone palmitate Invega Sustenna Paliperidone palmitate Invega Trinza Paliperidone palmitate Orap Pimozide Pimozide Pimozide Quetiapine Quetiapin Quetiapine - extended release Quetiapin quetiapine fumarate Quetiapin Seroquel Quetiapin Quetiapin Quetiapine extended-release Quetiapine fumarate Quetiapine fumarate Quetiapine fumarate - extended release Quetiapine fumarate Ceroquel Quetiapine fumarate Seroquel - XR Quetiapine fumarate Seroquel XR Quetiapine fumarate Quetiapine fumarate ER Quetiapine Fumarate ER Perseris Risperidone Risperdal Risperidon Risperdal Consta Risperidon Risperdal M-tab Risperidon Risperidon Risperidon Risperidone M-tab Risperidon Rykindo Risperidon Uzedy Risperidon Geodon Ziprasidone Ziprasidone Ziprasidone Ziprasidone hydrochloride Ziprasidone hydrochloride (ziprasidone hcl) Geodon Ziprasidone hydrochloride Ziprasidone Ziprasidone hydrochloride Geodon Ziprasidone mesylate Ziprasidone mesylate Ziprasidone mesylate

[0154] The donor cohort is in silico (to verify the fitness of individuals selected for the study) in silicoIt was evaluated using a manual approach. Due to the vast amount of medical information and the number of subjects considered for this study, an in silico framework was used to identify outliers for an in-depth evaluation of their medical information in the donor-PD and control cohorts. The aforementioned in silico approach utilized network analysis of donor similarity in medical history based on RWD. This analysis encompassed the evaluation of comorbidities and medication patterns, facilitating the identification and exclusion of mislabeled donors and atypical PD cases. Furthermore, each donor's health journey was manually reviewed by PD experts, which led to the final selection of donors with developed PD.

[0155] In compliance with the digital twin concept, a similar number of paired control samples were identified based on demographics and sample availability. Concomitant diagnoses for major diseases such as diabetes and hypertension were matched, and patients with all major central nervous system disorders (Table 3) were excluded from the control group. Approximately 2,600 samples from a total of about 700 subjects were selected for in-depth molecular profiling, ensuring a comprehensive and representative dataset to advance the understanding of PD.

[0156] Examples 5: Plasma exchange biobank using real-world data In the object Identifying the in-depth characteristics of PD occurrence

[0157] In order to uncover new analytes of PD and identify potential therapeutic targets and pathways, it was essential to obtain an accurate understanding of PD onset and associated comorbidities. The limitations of small datasets available from conventional resources were overcome by analyzing RWD from an extensive sample cohort from the aforementioned plasmapheresis biobank, along with claims data and EHRs of approximately 1.3 million individuals with PD, which provided a unique opportunity to decipher the multifaceted nature of PD onset and progression.

[0158] Deep molecular profiling of 2,609 samples from PD and control subjects was performed by deep proteomic profiling of individuals with developing PD and their respective paired control samples (see Fig. 16). The proteomics used for the analysis of these samples utilized the previously used Olink Explore HT (5k) (Olink, Uppsala, Sweden) and SomaScan assay v5 (Somalogic, Boulder, CO, USA) platforms, as well as Biognosys, a platform providing proteomic solutions for drug development using mass spectrometry. TM TrueDiscovery TM (Biognosys, Newton, MA, USA), and Alamar Biosciences' NULISAseq CNS disease panel (Alamar Biosciences, Fremont, CA, USA), a CNS disease target panel using multiple quantification, were included. These different proteomic platforms were shown to provide complementary signals, and their combination enables the investigation of approximately 15,000 proteins. These molecular changes were correlated with medical records from RWD to integrate molecular and proteomic analyses with available clinical and phenotypic data for the subjects.

[0159] Samples were identified at all stages of PD progression, including prior to the identified clinical onset (Figs. 17a and 17b). A total of 348 PD donors with 1,323 samples were identified. 245 individuals (70%) associated with a total of 913 samples were identified as having at least one sample donated prior to the first physician visit associated with a G20 code. 135 individuals (39%) associated with a total of 410 samples were identified as having at least one sample donated after the first physician visit associated with a G20 code. 32 individuals (95) associated with a total of 207 samples had at least one sample donated prior to the first physician visit and at least one sample donated afterward, and these were identified as being associated with a G20 code.

[0160] Partial least squares discriminant analysis (PLS-DA) was performed on both PD samples and control samples. The PLS-DA revealed proteome variations in all samples over time, but also revealed specific variations of certain proteins in PD samples compared to their matched control samples (Fig. 18).

[0161] Although the foregoing invention has been described in some detail as examples and embodiments for clarity of understanding, it is immediately apparent to those skilled in the art that specific changes and modifications can be made without departing from the spirit or scope of the appended claims in light of the teachings of the present invention.

[0162] Accordingly, the foregoing merely illustrates the principles of the invention. It will be understood that a person skilled in the art may devise various configurations that embody the principles of the invention and fall within the spirit and scope thereof, even though they are not explicitly described or illustrated herein. Furthermore, all examples and conditional expressions cited herein are intended primarily to help the reader understand the principles of the invention and the concepts to which the inventors have contributed to the development of the art, and should be interpreted as not being limited to such specifically cited examples and conditions. Moreover, all statements in this application citing specific examples, as well as the principles, modes, and embodiments of the invention, are intended to encompass all structural and functional equivalents thereof. Additionally, such equivalents are intended to include all currently known equivalents and equivalents to be developed in the future, that is, any developed elements that perform the same function regardless of structure. Furthermore, nothing disclosed herein is intended to be made public, regardless of whether such disclosure is explicitly cited in the claims.

[0163] Accordingly, the scope of the present disclosure is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of the present disclosure are embodied by the appended claims. In the claims, 35 USC §112(f) or 35 USC §112(6) is explicitly defined to be invoked for the limitation only where the exact phrase “means for” or the exact phrase “step for” is cited at the beginning of such limitation within the claim; where such exact phrase is not used in the limitation within the claim, 35 USC §112(f) or 35 USC §112(6) is not invoked.

Claims

Claim 1 A method for identifying an analyte associated with a phenotype of interest using a computer system comprising one or more processors and system memory, the method comprising: using the one or more processors to select two or more end-data sets in a database derived from one or more end-sample sets, wherein the end-sample sets comprise samples from individual subjects collected over a specified period; using the one or more processors to determine one or more analyte scores from a plurality of analytes detected in the end-data sets, wherein the analyte scores are correlated with the phenotype of interest; and using the one or more processors to identify one or more analytes associated with the phenotype of interest based on the analyte scores for each end-data set. Claim 2 A method according to claim 1, wherein data derived from a sample of the above-mentioned sample set is stored in the database along with additional information that may be associated with the sample donor. Claim 3 A method according to paragraph 2, wherein the additional information in the database regarding the sample of the above-mentioned end sample set is de-identified. Claim 4 A method according to claim 1, further comprising the step of obtaining a longitudinal data set from two or more longitudinal sample sets, wherein the longitudinal data set is stored in a database. Claim 5 A computer system comprising one or more processors; system memory; and one or more computer-readable storage media, wherein the one or more computer-readable storage media store computer-executable instructions that, when executed using the one or more processors, enable the computer system to implement a method for identifying a gene associated with a disease-related phenotype of interest, and wherein the method is the method of any one of claims 1 to 4. Claim 6 A computer system comprising one or more processors; system memory; and one or more computer-readable storage media, wherein the one or more computer-readable storage media store computer-executable instructions that, when executed using the one or more processors, enable the computer system to implement a method for identifying a terminal data set associated with a phenotype of interest, wherein the method comprises: (a) using the one or more processors to select two or more terminal data sets in a database derived from one or more terminal sample sets, wherein the terminal sample sets comprise samples from a plurality of subjects collected over a specified period; (b) using the one or more processors to determine one or more analyte scores from a plurality of analytes detected in the terminal data sets, wherein the analyte scores are correlated with the phenotype of interest; and (c) using the one or more processors to identify one or more analytes associated with the phenotype of interest based on the analyte scores for each terminal data set. Claim 7 In paragraph 6, a system in which the method for identifying a longitudinal data set associated with a phenotype of interest further utilizes additional information within the database regarding samples of the longitudinal sample set. Claim 8 A system according to claims 6 and 7, wherein the method for identifying a longitudinal data set associated with a phenotype of interest further comprises additional information that may be associated with the sample donor. Claim 9 A system in which, in paragraphs 7 and 8, the additional information in the database regarding the samples of the above-mentioned end sample set is de-identified. Claim 10 A library of plasma exchange samples comprising a plurality of end-sample sets, wherein each end-sample set comprises a plurality of samples obtained from the same donor over a certain period, and wherein the samples are obtained by plasma exchange.